Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Antiviral Res. 2011 Sep 8;92(2):329–340. doi: 10.1016/j.antiviral.2011.09.001

Figure 4.

Figure 4

Evaluation of higher dose of 2’FdC for efficacy against a highly pathogenic influenza H5N1 virus infection in BALB/c mice. Vehicle placebo, 2’-deoxy-2’-fluorocytidine, or ribavirin were administered intraperitoneally. Experimental groups, n = 10; placebo group, n = 15. 0.4% CMC (●), 2'-FdC at 60 (■). 30 (▲) or ribavirin at 75 mg/kg/day (○) (bid × 8), beginning −24 h relative to virus exposure. ** P= 0.0014, 2'-FdC (60 mg/kg); ** P=0.0016, 2'-FdC (30 mg/kg −24), ** P=0.0013 (ribavirin, 75 mg/kg/d).